p-Tau217 might be the Benjamin Button of biomarkers—starting off old and ending up young. Seriously, p-tau217 is unusually high at birth before waning with age, scientists report. In a cross-sectional ...

Two studies analyzed tau-PET scans from thousands of participants in dozens of cohorts. Tangle prevalence increased with age among cognitively normal people, but decreased among those with dementia.

The role of ApoE has been well-studied outside of the cell, but what happens after it’s let inside? Scientists led by Raimund Dutzler, University of Zurich, have identified Tweety homologue 2 as an ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

Brain Shuttle Sneaks Gantenerumab Past the Blood-Brain Barrier Initially, gantenerumab was nearly scuttled when low doses failed to budge endpoints in the Phase 3 Scarlet RoAD and Marguerite RoAD ...

The virus–Alzheimer’s tug of war continues. New data across several studies weaken the proposed, and much-debated, association; its proponents are holding fast. Short-term anti-herpes drug use ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Results of the eagerly awaited Phase 3 clinical trial of LMTM, a derivative of the dye methylene blue, generated consternation at the Alzheimer’s Association International Conference 2016, held July ...

In older women, brief suspensions of respiration during sleep (apnea) may cause more than daytime drowsiness, increased cardiovascular risk, and insulin resistance—it may also lead to mild cognitive ...